Zacks Investment Research Upgrades Bicycle Therapeutics (NASDAQ:BCYC) to Hold

Dovie Salais

Zacks Investment Research upgraded shares of Bicycle Therapeutics (NASDAQ:BCYC) from a sell rating to a hold rating in a report released on Friday, Zacks.com reports. According to Zacks, “Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company. It is focused on developing medicines, referred to as Bicycles(R) for diseases which are […]

Zacks Investment Research upgraded shares of Bicycle Therapeutics (NASDAQ:BCYC) from a sell rating to a hold rating in a report released on Friday, Zacks.com reports.

According to Zacks, “Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company. It is focused on developing medicines, referred to as Bicycles(R) for diseases which are underserved by existing therapeutics. Bicycle Therapeutics plc is based in Cambridge, United Kingdom. “

A number of other research firms have also issued reports on BCYC. Oppenheimer restated a buy rating and issued a $27.00 price target on shares of Bicycle Therapeutics in a research report on Tuesday, September 22nd. HC Wainwright reiterated a buy rating and issued a $25.00 price objective on shares of Bicycle Therapeutics in a report on Thursday, August 6th. Cantor Fitzgerald assumed coverage on Bicycle Therapeutics in a research note on Monday, October 12th. They set an overweight rating and a $30.00 price target on the stock. BidaskClub upgraded Bicycle Therapeutics from a hold rating to a buy rating in a research note on Saturday, October 31st. Finally, Canaccord Genuity upped their price target on Bicycle Therapeutics from $23.50 to $25.00 and gave the stock a buy rating in a research note on Thursday, September 10th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Bicycle Therapeutics has an average rating of Buy and an average target price of $23.67.

NASDAQ:BCYC opened at $18.49 on Friday. Bicycle Therapeutics has a 12 month low of $7.50 and a 12 month high of $21.59. The stock has a 50 day moving average of $19.15 and a two-hundred day moving average of $17.07. The firm has a market cap of $327.27 million, a P/E ratio of -8.93 and a beta of -0.35.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.52). Bicycle Therapeutics had a negative return on equity of 43.74% and a negative net margin of 434.29%. Analysts anticipate that Bicycle Therapeutics will post -2.49 earnings per share for the current year.

A number of large investors have recently made changes to their positions in BCYC. Morgan Stanley lifted its position in shares of Bicycle Therapeutics by 32,450.0% during the 1st quarter. Morgan Stanley now owns 3,255 shares of the company’s stock valued at $44,000 after acquiring an additional 3,245 shares during the period. UBS Group AG purchased a new position in shares of Bicycle Therapeutics during the 2nd quarter worth approximately $36,000. FMR LLC purchased a new position in shares of Bicycle Therapeutics during the 2nd quarter worth approximately $3,277,000. Advisor Group Holdings Inc. increased its stake in shares of Bicycle Therapeutics by 34,000.0% during the 2nd quarter. Advisor Group Holdings Inc. now owns 34,100 shares of the company’s stock worth $537,000 after purchasing an additional 34,000 shares in the last quarter. Finally, California Public Employees Retirement System increased its stake in shares of Bicycle Therapeutics by 8.5% during the 3rd quarter. California Public Employees Retirement System now owns 20,345 shares of the company’s stock worth $388,000 after purchasing an additional 1,600 shares in the last quarter. Hedge funds and other institutional investors own 35.54% of the company’s stock.

About Bicycle Therapeutics

Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.

See Also: What is the CBOE Russell 2000® Volatility Index?

Get a free copy of the Zacks research report on Bicycle Therapeutics (BCYC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Bicycle Therapeutics (NASDAQ:BCYC)

Receive News & Ratings for Bicycle Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bicycle Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Source Article

Next Post

TI Introduces Automotive GaN FET with Integrated Driver, Protection, and Active Power Management

Semiconductors aimed at the automotive and industrial sectors have been coming at us at a fast and furious pace. Here is yet another example: Texas Instruments recently expanded its family of high-voltage power-management devices with the introduction of 600- and 650-V gallium nitride (GaN) FETs, dubbed the LMG3425R030. There are […]

Subscribe US Now